Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
11/21/2007
Trade Name:
Omnaris Nasal Spray
Generic or Proper Name (*):
ciclesonide
Indications Studied:
Treatment of seasonal allergic rhinitis (SAR) in patients 6 through less than 12 years of age
Therapeutic Category:
Antihistamine
Ages Studied:
2-12 years
Study #:
1
Study Type:
Safety/Tolerability
Study Design:
Single-Blind/Placebo/Parallel Group
No Patients:
125
No Centers:
3
No Countries:
1
BPCA(B), PREA(P):
P
-
-